Fundraising FoxVivo Capital — 2018 Investments
8 investments dated 2018 · listed companies and verified rows first · show all
Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
BiotechSan Diego, US
Richard Scott Struthers(Executive Officer, Director)Stephen Betz(Chief Scientific Officer)inR. Scott Struthers(President, Chief Executive Officer and Director)inTobin Schilke(Chief Financial Officer)inIsabel Kalofonos(Chief Commercial Officer)inYunFei Zhu(Executive Officer)
Board seatJack Nielsen· per SEC Form D
Co-investors5AM VenturesForesite CapitalOrbiMedRA Capital
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.
BiotechHealthtechMorristown, US
Scott Giacobello(Executive Officer)inBryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)inDavid Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)
Co-investors3B Future Health FundAlly Bridge GroupDecheng CapitalOrbiMed
BiotechSan Diego, US
Francois Ferre(Director)Magda Marquet(Director)Jorge Garces(Executive Officer)inGreg Hamilton(Executive Officer, Director)Carin Sandvik(Executive Officer)Jeffrey G. Black(Executive Officer)
Board seatYuh-geng Tsay· per SEC Form D · $3M raise · filed Mar 2018
Co-investorsBioBritTelegraph Hill PartnersAlly Bridge GroupWuXi Healthcare Ventures
Amyris develops a biomanufacturing platform that uses fermentation and microbial engineering to produce natural ingredients and rare compounds at scale for partners across industries such as specialty chemicals, food ingredients, and consumer products.
Advanced ManufacturingBiotechCleantechNew MaterialsEmeryville, US
NICHOLAS KHADDER(Senior Vice President, General Counsel & Secretary)RAFFI ASADORIAN(Chief Financial Officer)inJoel Cherry(President, Research & Development)inTamara Tompkins(Executive Vice President, General Counsel)inJohn Melo(President & Chief Executive Officer)inPaulo Diniz(Chief Financial Officer)in
Board seatFrank Kung· per SEC Form D
Co-investorsKleiner PerkinsMaple Leaf AngelsR7 Partners
Lite Strategy, Inc.
BiotechCrypto & Web3FintechHealthtechSan Diego, US
David M. Urso(Executive Officer)inDaniel P. Gold(Executive Officer, Director)Brian G. Drazba(Executive Officer)inMr. File(Chief Executive Officer & Board Member (former CFO))Justin (Jay) File(CEO, CFO)inKevan E. Clemens(Director)
Co-investors3B Future Health FundAisling CapitalGSRNew Enterprise Associates (NEA)Primitive VenturesAmzak Health+1 more
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Co-investorsage1EcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)+8 more
Ossium Health develops cellular therapies and bioengineered products for clinical use, leveraging adult stem cell technologies and advanced cell processing platforms.
BiotechHealthtechMedical DevicesSan Francisco, US
Kevin Caldwell(Founder)inDr. Woods(Chief Science Officer, Co-Founder, EVP, CLIA Laboratory Director)Sebastian Giwa(Director)inErik Woods(Founder)in
BoardWilliam Trenchard(Director)inThomas Cycyota(Director)
Co-investorsAlumni VenturesFemHealth VenturesFirst Round CapitalGaingelsGeneral CatalystHemisphere Ventures LLC+5 more
__Twitter.png)
.png)
Poseida Therapeutics develops cell therapy candidates and related platform technologies for healthcare applications.
BiotechHealthtechSan Diego, US
Eric Ostertag(Executive Officer, Director)Mark Gergen(Executive Officer, Director)
BoardAdrian Howd(Director)David Hirsch(Director)
Co-investorsAisling CapitalLongitude CapitalRapha Capital Management, LLC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.